Nama's AI scorecard currently rates Haleon Buy (6.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is HLN's P/E ratio?

Haleon trades at a trailing price-to-earnings ratio of 21.3.

What is the HLN price target?

The median analyst price target from 5 analysts is $10.40, with a range of $9.79 – $11.40.

Is HLN Shariah compliant?

Nama's AAOIFI-style screen reads Haleon as Can't Tell. A figure the screen needs is missing, so it can't tell.

Does HLN pay a dividend?

Yes — Haleon's dividend yield is 2.2%.

Nama Insights

Haleon (HLN)

Healthcare · Drug Manufacturers Specialty Generic · NYSE

Haleon (HLN) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $40.17B, a trailing price-to-earnings ratio of 21.3 and a free-cash-flow yield of 7.2%. Over the most recent reported fiscal year, revenue declined 1.8% and free cash flow per share grew 14.0%. Nama's AI scorecard rates it Buy, 6.2 out of 10. On 12-month momentum it ranks in the lagging band of its market.

AI scorecard

Buy · 6.2/10

Positive, at the low end of Buy. As of Nov 7, 2026.

Momentum

Lagging · -4.1% over 12 months ex. last

Second-worst fifth of its market on the past year's move.

Shariah screen

Can't Tell

A figure the screen needs is missing, so it can't tell.

Off its high

-20.0%

How far the last close sits under the highest price of the past five years.

Market cap	$40.17B
Trailing P/E	21.3
Price / book	3.7
Price / sales	2.7
FCF yield	7.2%
Dividend yield	2.2%
Gross margin	65.6%
Operating margin	23.9%
Net margin	14.6%
Revenue growth (YoY)	-1.8%
Revenue growth (3-yr annual)	+0.5%
EPS growth (YoY)	—
FCF/share growth (YoY)	+14.0%
Beta	0.3
Exchange	NYSE
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

HLN earnings

Beat the EPS estimate in 2 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2024	Oct 31, 2024	$0.12	$0.11	+9.1%	—
Q2 2024	Aug 1, 2024	$0.10	$0.09	+11.1%	—
Q4 2023	Feb 29, 2024	$0.10	$0.13	-23.1%	—
Q3 2023	Nov 2, 2023	$0.11	$0.12	-8.3%	—

HLN analyst price target

Median target $10.40 from 5 analysts, ranging $9.79 – $11.40.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3
RDY	Dr. Reddy's Laboratories	$12.43B	20.4

Explore live HLN data on Nama Insights →

Recent Congressional trades

Haleon trades disclosed by members of the US House and Senate under the STOCK Act. See the full Congress trades board →

Member	Chamber	Trade	Amount	Disclosed
Valerie Hoyle	House	Sell	$1,001 - $15,000	Oct 10, 2025
Valerie Hoyle	House	Buy	$1,001 - $15,000	Sep 12, 2025
Lisa McClain	House	Sell	$1,001 - $15,000	Aug 13, 2025
Lisa McClain	House	Buy	$1,001 - $15,000	Aug 13, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	May 14, 2025
Josh Gottheimer	House	Sell	$1,001 - $15,000	Jul 9, 2024
Josh Gottheimer	House	Buy	$1,001 - $15,000	Jun 8, 2024
Josh Gottheimer	House	Buy	$1,001 - $15,000	Aug 21, 2023
Josh Gottheimer	House	Buy	$1,001 - $15,000	Aug 21, 2023
Josh Gottheimer	House	Buy	$1,001 - $15,000	Aug 21, 2023
Daniel Goldman	House	Sell	$15,001 - $50,000	Aug 13, 2023

HLN FAQ

Is HLN a buy?: Nama's AI scorecard currently rates Haleon Buy (6.2 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is HLN's P/E ratio?: Haleon trades at a trailing price-to-earnings ratio of 21.3.
What is the HLN price target?: The median analyst price target from 5 analysts is $10.40, with a range of $9.79 – $11.40.
Is HLN Shariah compliant?: Nama's AAOIFI-style screen reads Haleon as Can't Tell. A figure the screen needs is missing, so it can't tell.
Does HLN pay a dividend?: Yes — Haleon's dividend yield is 2.2%.